[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid‐β pathology

Alzheimer's & Dementia - Tập 11 - Trang 975-985 - 2015
Dietmar Rudolf Thal1, Thomas G. Beach2, Michelle Zanette3, Kerstin Heurling4,5, Aruna Chakrabarty6, Azzam Ismail6, Adrian P.L. Smith7, Christopher Buckley7
1Institute of Pathology—Laboratory of Neuropathology, Center for biomedical Research, University of Ulm, Ulm, Germany
2Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA
3Life Sciences R&D Biometrics, GE Healthcare, Princeton, NJ, USA
4Life Sciences R&D, GE Healthcare, Uppsala, Sweden
5Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden
6Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, St. James Hospital, Leeds, UK
7Life Sciences R&D, GE Healthcare, Amersham, UK

Tóm tắt

AbstractBackgroundAmyloid positron emission tomography (PET) has become an important tool to identify amyloid‐β (Aβ) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [18F]flutemetamol in relation to Aβ pathology at autopsy.Methods[18F]flutemetamol PET was carried out in a cohort of 68 patients included in a [18F]flutemetamol amyloid PET imaging end‐of‐life study (GE067‐007). At autopsy, AD pathology was determined and Aβ plaque pathology was classified into phases of its regional distribution (0–5).Results[18F]flutemetamol PET was universally positive in cases with advanced stage postmortem Aβ pathology (Aβ phases 4 and 5). Negative amyloid PET was universally observed in nondemented or non‐AD dementia cases with initial Aβ phases 1 and 2, whereas 33.3% of the phase 3 cases were positive.Conclusions[18F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases.

Tài liệu tham khảo

10.1016/S0006-291X(84)80190-4 10.1073/pnas.82.12.4245 10.1002/ana.20009 10.1007/s00401-012-1051-z Zeng F, 2013, Fluorine‐18 radiolabeled heterocycles as PET tracers for imaging beta‐amyloid plaques in Alzheimer's disease, Curr Top Med Chem, 13, 909, 10.2174/1568026611313080004 10.1097/WAD.0b013e31821300bc 10.1523/JNEUROSCI.2990-05.2005 10.1093/brain/awn016 10.1016/S1474-4422(12)70142-4 10.1001/jamaneurol.2014.4144 10.1212/WNL.58.12.1791 10.1016/j.jalz.2011.10.007 10.1016/j.jalz.2011.03.005 10.1016/j.jalz.2011.03.003 Thal DR, 2013, Pathology of clinical and preclinical Alzheimer's disease, Eur Arch Psychiatry Clin Neurosci, 263, S137, 10.1007/s00406-013-0449-5 10.1093/brain/awt362 10.1002/ana.22068 10.1007/s00401-009-0485-4 10.1007/s00401-014-1349-0 10.1111/j.1582-4934.2008.00411.x 10.1093/brain/awt286 10.1016/S1474-4422(12)70227-2 10.1016/j.nicl.2013.02.006 10.1016/j.neuropsychologia.2008.02.008 10.1093/brain/awu367 10.1016/S0065-1281(11)80100-5 10.1097/01.jnen.0000229986.17548.27 10.1007/s00259-014-2753-3 10.1007/s00401-008-0358-2 10.1007/s00259-012-2178-9 10.1007/s11307-012-0583-x 10.1001/archneurol.2011.153 10.1016/j.neurobiolaging.2009.02.011 10.1007/s00401-013-1185-7 10.1007/BF00308809 10.1212/WNL.41.4.479 10.1007/s00401-009-0612-2 10.1046/j.1440-1789.2003.00522.x
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 11

975-985

Thông tin tác giả